<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) is a life-threatening condition wherein bone marrow transplantation (BMT) is the therapy of choice in a young patient who has a matched sibling donor </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we report an 11-year-old boy with severe AA who was referred for BMT late in its course when he had developed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> following two courses of immunosuppressive therapy with antithymocyte globulin and cyclosporin </plain></SENT>
<SENT sid="2" pm="."><plain>He was then treated with induction therapy using <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> and daunomycin for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, but he succumbed due to <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and refractory <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We discuss the relevance of early referral for BMT in severe AA </plain></SENT>
</text></document>